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http://www.biologydirect.com/content/8/1/29DISCOVERY NOTES Open AccessHighly homologous eEF1A1 and eEF1A2 exhibit
differential post-translational modification with
significant enrichment around localised sites of
sequence variation
Dinesh C Soares1,2* and Catherine M Abbott2*Abstract
Translation elongation factors eEF1A1 and eEF1A2 are 92% identical but exhibit non-overlapping expression
patterns. While the two proteins are predicted to have similar tertiary structures, it is notable that the minor
variations between their sequences are highly localised within their modelled structures. We used recently available
high-throughput “omics” data to assess the spatial location of post-translational modifications and discovered that
they are highly enriched on those surface regions of the protein that correspond to the clusters of sequence variation.
This observation suggests how these two isoforms could be differentially regulated allowing them to perform distinct
functions.
Reviewers: This article was reviewed by Frank Eisenhaber and Ramanathan Sowdhamini.
Keywords: eEF1A1, eEF1A2, Phosphorylation, Methylation, Acetylation, Ubiquitination, Post-translational modificationBackground
Translation is the mechanism by which the cell accom-
plishes de novo protein synthesis. The elongation stage is
where aminoacylated-tRNAs (aa-tRNA) are delivered to
the ribosome, is accomplished by elongation factor 1A,
or eEF1A, which is the second most abundant protein in
the cell; the role of eEF1A is GTP dependent, and this
process is facilitated by a GTP-exchange factor called
eEF1B. In vertebrates, eEF1A occurs in one of two differ-
ent isoforms (eEF1A1 and eEF1A2) each encoded by a
separate locus, and each with a distinct expression pat-
tern [1,2]. These two isoforms are 92% identical and 98%
similar to each other at the amino acid level. eEF1A1 is
almost ubiquitously expressed except in neurons and
muscle (skeletal and cardiac), where eEF1A1 declines to
undetectable levels and is gradually replaced by eEF1A2
during postnatal development [3]. This expression* Correspondence: Dinesh.Soares@ed.ac.uk; C.Abbott@ed.ac.uk
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distribution, and reproduction in any mediumpattern correlates perfectly with the onset of neuromus-
cular abnormalities in wasted mice [3]. Biochemically,
the two isoforms appear to operate in a similar manner;
they have indistinguishable activities in an in vitro trans-
lation system, but eEF1A2 shows much greater affinity
for GDP than GTP, whereas eEF1A1 has a greater affin-
ity for GTP [4]. We recently used comparative homology
modelling to map those amino acids that differ between
the two isoforms onto their tertiary structures. This
revealed that the non-conserved residues appear in
discrete surface clusters that do not overlap with the
binding site for eEF1Balpha [5].
A crucial question is why eEF1A1, which is highly con-
served throughout evolution, widely expressed, and is an
abundant and essential protein, should be switched off
in certain tissues at specific developmental stages and
replaced with an almost, but not quite, identical and
equally highly conserved protein? One possible explan-
ation is that eEF1A1 has additional “moonlighting” or
non-canonical, functions that may not be shared by
eEF1A2, and that might in fact be deleterious to certain
cell types.entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.biologydirect.com/content/8/1/29What are these non-canonical functions? It has been
demonstrated that eEF1A1 can interact with and modify
the cytoskeleton [6]. If on the other hand eEF1A2 did
not share these properties, this would fit well with the
nature of many of the cell types that we know undergo
this switch - they tend to be cells with a very stable and
complex architecture. However, there are now many
other examples of non-canonical functions for eEF1A1,
few of which have been investigated with respect to
eEF1A2. Roles have also been identified for eEF1A1 in
viral propagation, proteolysis, nuclear transport and
apoptosis [7], but it is important to note that some of
these roles may not be truly non-canonical, in that they
may not be independent of the role of eEF1A1 in trans-
lation; one of the challenges for the field is to start to
address these subtleties. eEF1A1 has been found to be
crucial for the function of many viruses [8] whereas
eEF1A2 is not known to fulfil a similar role. eEF1A2 is a
putative oncogene; it has been shown to be capable of
transforming cells that are already expressing high levels
of eEF1A1, suggesting that the two proteins may have
different roles in tumourigenesis [9]. Disentangling the
non-canonical functions with respect to each of the two
isoforms is crucial because of the distinct roles they play
in disease.
Findings
We previously mapped known and variable (potential)
phosphorylation sites on comparative models of eEF1A1
and eEF1A2. Since that report, high-throughput “omics”
studies using tandem mass spectrometry have emerged
that have uncovered additional novel phosphorylation
sites, as well as sites of acetylation, methylation and ubi-
quitination. Based on literature and the PhosphoSitePlus
database [10], we have now mapped these new data to
our models. This exercise revealed interesting differ-
ences in post-translational modifications (PTMs) be-
tween the two variants. These include examples of
altered acetylation, phosphorylation, S-nitrosylation and
ubiquitination that can only occur in one of the variants.
These are shown mapped on a modelled structure in
Figure 1 (and on a multiple sequence alignment in
Additional file 1; tabulated in Additional file 2). Specific-
ally, T176A can only be phosphorylated in eEF1A1,
C234T can be S-nitrosylated only in eEF1A1 but can be
phosphorylated in eEF1A2, K273R can only be acetylated
and ubiquitinated in eEF1A1. More recently one of our
predicted sites of phosphorylation, S358A that is specific
to eEF1A2 [5], was experimentally confirmed [11].
There are 74 post-translationally modified positions in
total. Seven of these are located within the C-terminal
disordered region of the protein [5], while a total of 67
sites can be mapped onto the 3-D model of eEF1A1 for
analysis. Out of these 67 sites, 56 modified residues arelargely or partly exposed on the surface of the protein
(Figure 1). The vast majority of PTMs map on to the
“variable face” of the protein and many lie either within or
close to the two clusters of sequence variation between
eEF1A1 and eEF1A2 (Additional file 3). The “variable
face” has a total of 37 modified residues, compared with
just 19 such residues seen on the “conserved face” of the
protein – an almost two-fold increase. A total of 24 sites
are modified by more than one receptor implying com-
petition between modifying enzymes (Additional file 1).
Taking into consideration residues that can be alterna-
tively modified the “conserved face” displays 28 possible
modifications amongst 19 residues, while the “variable
face” supports a total of 53 modifications. This obser-
vation is surprising considering the number of PTMs
present. Figure 1 has been systematically redrawn in each
panel with the new PTM shown on the surface where they
overlap to aid the viewer to distinguish between different
PTM-types.
Some of the PTMs overlap with known binding sites
from experiments conducted in yeast eEF1A (Figure 1,
Panel E). These include S21, T22, K154, S157 (GTP/
GDP-binding site), S76 (eEF1Balpha-binding site; note
Alanine (A76) is present at this equivalent position in
yeast), R166 (mutant reduces dependence on eEF1B),
N331S, M335Q and Y357 (mutants involved in actin
bundling/organisation). Interestingly, there are only two
residues (24 out of 26 are strictly conserved) that are
altered between yeast and human eEF1As for the
eEF1Balpha-binding site. These are: S76 in human, A76
in yeast; and I89 in human, V89 in yeast. The latter is a
conservative substitution, but the observation that S76 is
apparently phosphorylated in human eEF1A but not in
yeast may thus suggest differential binding or regulation
with eEF1Balpha. The effect of this single amino acid
substitution in the human eEF1A1-eEF1Balpha interaction
should be tested. There already exists evidence for post-
translational modulation of function for the eEF1As; phos-
phorylation at S300 by TGFbetaR-1 was shown to prevent
aa-tRNA binding to eEF1A1 [12] (Figure 1, Panel B), and
mono-O-glucosylation at S53 in eEF1A is known to inhibit
protein synthesis [13] (Figure 1, Panel D).
Another notable observation is that the “base” (see
variable-face view) of the molecule is very highly enriched
for lysine and arginine modification (acetylation, methyla-
tion, ubiquitination). There is also another surface on the
“left” (see conserved-face view) that forms an extended
binding region for the modifying molecules. Analysis of
our previously undertaken electrostatic surface mapping
on the eEF1A1 and eEF1A2 model molecules [5] in this
context reveals some important changes. These involve
charged amino acids that occur in immediate proximity to
acetylation, methylation and ubiquitination sites only on
the “variable face” of the molecules. Specifically, these are
Figure 1 Post-translational modification and eEF1A1 and eEF1A2. All known PTMs are mapped on the surface of the 3-D model of eEF1A1
are shown in the two views (the “conserved face” and the “variable face”) rotated by 180° about the y-axis: (A) location of variant amino acids
between eEF1A1 and eEF1A2 (green); (B) phosphorylation sites (orange); (C) acetylation (blue), methylation (blue), ubiquitination (blue) and
ethanolamination (yellow) sites; (D) S-nitrosylation (red), S-glutathionylation (red) and O-glucosylation sites (pink); (E) overlap of post-translational
modifications with known binding sites (brown) and altered PTMs between eEF1A1 and eEF1A2 (black). All surface-exposed variant amino acid
residues between eEF1A1 and eEF1A2 and PTMs are labelled; where a residue is modified in more than one way or altered between the two
isoforms, this is indicated on the residue (a = acetylated; m =methylated; n = S-nitrosylated; p = phosphorylated; t = S-glutathionylated; u = ubiquitinated).
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http://www.biologydirect.com/content/8/1/29D186A and D417Q - negative charge in eEF1A1, absent
in eEF1A2, and Q164E and T217E - negative-charge
in eEF1A2, absent in eEF1A1. These could impart different
molecular recognition properties to the modifying
molecule.
Not all of the post-translationally modified residues
are surface exposed (a total of 11 out of 67 are com-
pletely buried), indicating that the protein adopts dif-
ferent conformations depending on its bound versus
unbound state (for example with eEF1B) that reveal or
conceal sites targeted by the modifying proteins. It is
possible that local conformational changes or structural
rearrangements may underlie greater surface accessibil-
ity for some of these buried sites [14]. Moreover, the
active site of the protein-modifying enzyme needs to ac-
cess the target residue on the substrate; this situation
could be made more likely if the substrate existed in a
less compact state or if modification occurred prior to
protein folding [15,16]. Indeed, a previous study by Bud-
kevich et al. [17] provided evidence that the native
eEF1A1 isoform possesses a non-globular extended con-
formation in solution that changes to a more compact
conformation upon interaction with tRNAs.
An example of a divergent, functionally important
patch is the region that contains the ethanolamination
site E301 [18,19], the competitive (altered) acetylation
and ubiquitination site K273R, the phosphorylated site
S300 (known to prevent aa-tRNA binding) [12,20] and
two variants between eEF1A1 and eEF1A2 (N331S and
M335Q, Figure 1 “variable face”) that impact on actin
binding and bundling properties (from yeast mutagenesis
data [21,22] – summarised on structure in Soares et al.
2009 [5]). Additional comparative sequence analysis, of
vertebrate eEF1A1 and eEF1A2 with yeast eEF1A, reveals
clear evidence for alterations in post-translational modifi-
cations between them (Additional file 1). Hence, the pres-
ence of the two distinct cell type-specific isoforms in
vertebrates creates the potential for greater functional
complexity than is seen in yeast.
We mapped all known PTM data on the 3-D models
of eEF1A1 and eEF1A2. We note that while the Phos-
phoSitePlus resource is based upon experimental, manu-
ally curated data there remains a possibility for false
positives, particularly from the large-scale mass spectro-
metric studies. Experimental verification of PTMs dis-
covered by mass spectrometry will be needed using
additional complementary techniques. It is also of note
that many of the studies have been performed on human
tumour or cancer cell line material; it is therefore con-
ceivable that some of these PTMs may be specific to
tumours, depending on the relative expression of differ-
ent modifying enzymes in cancerous and normal cells.
Additionally, while a large body of PTM data is available
for these two proteins (Additional file 2) new sites arestill being discovered. For example the aforementioned
eEF1A2-specific phosphorylation of S358 [11] was not
observed in the high-throughput proteomics screens.
Hence, false negatives are also possible given the sensi-
tivity of the methodology [14]. Owing to the very high
sequence identity between eEF1A1 and eEF1A2, it is
currently almost impossible to judge whether the experi-
mentally identified post-translationally modified peptides
originated from one isoform or the other. Because so
many PTMs are located proximal to sites of sequence
variation on the surface of the protein (Additional file 3),
we speculate that the modified residues will in fact often
be isoform specific. Owing to the large number of clus-
tered PTMs it is likely that extensive cross-regulation
occurs [23-25]. Furthermore, the protein-modifying
enzymes involved could differ between the two isoforms,
even for sites that are identical in sequence. Examining
these possibilities remains a key future goal for research.
In a recent biophysical study that compared eEF1A1
and eEF1A2 [26], the authors noted the main difference
in structural properties of these proteins was an en-
hanced ability of eEF1A1 to self-associate. Thus even
though the two proteins are predicted to have similar
tertiary structure [5,27], their oligomeric states differ.
Furthermore, the authors established that eEF1A1 was
more hydrophobic in character than eEF1A2 [26]. The
authors postulated that differential phosphorylation may
underlie difference in self-association propensity for the
two proteins, and differential methylation profiles could
explain the increased hydrophobicity of eEF1A1 [26].
We suggest that the surprising enhancement of PTM in
the vicinity of surface clusters of sequence variation is
unlikely to have occurred by chance. It has likely evolved
to facilitate differentially tuneable properties, such as
structural or oligomeric propensity and regulation, and
thus functional divergence, allowing retention of two
non-redundant isoforms.Reviewers’ reports
We thank the reviewers for their useful feedback and
constructive comments for improvement of our manu-
script. We have considered all their suggestions and have
addressed these below.Reviewer 1: Dr. Frank Eisenhaber (Bioinformatics Institute,
Singapore)
In an earlier study, the authors concluded that the minor
sequence variations distinguishing eEF1A1 and eEF1A2
are confined in structurally limited sections of the two
proteins (mostly at what they call back side). Here, they
claim that these places harbour most of the PTMs. A few
mutations are suggested that might have an effect on
differential binding/regulation.
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finding might be incremental.
First of all, the authors operate at a quite qualitative
level. It would be good to consider in number terms how
many PTMs are in the sequence variation clusters, how
many are just nearby and how many are differentiated
between the two proteins. Together with some statistical
assessment, this would substantiate the main claim of
this work, namely the enrichment of PTMs in the clusters
of sequence variation.
Authors’ Response: The reviewer is right and we thank
them for making this point. In the revised text we make
clear 1) the total number of PTMs present, 2) how many
are surface exposed on each face of the protein, and 3)
what residues are subject to more than one form of
modification. This quantification substantiates our point
that PTMs are significantly more likely in locations close
to sites of sequence variation, on the “variable face” of
the protein, than elsewhere. From the number-counts
there is an almost two-fold increase in modifications on
the variable face of the protein (19 on the conserved
face; 37 on the variable face). The second paragraph of
the Findings section now reports and clarifies these re-
sults. We have also added in new Additional file 3:
“Post-translational modifications (PTMs) in structural
proximity to sequence variants between eEF1A1 and
eEF1A2” - to enumerate and specify which PTMs are
proximal to each variant using a structure-based 5-
Angstrom sphere-radius cut-off for each residue. We
have also revised Figure 1 (all PTM residues are now
labelled and further annotated if a specific residue can
be modified in more than one way) that now clearly
emphasises the non-random distribution of PTMs.
Second, the PTMs have been measured in varying bio-
logical contexts; some might be artifacts or only applic-
able to specific biological situations. It would be good to
have a separate consideration as detailed above for the
PTMs that might be considered most reliable and most
likely to be biologically significant.
Authors’ Response: We completely agree with the
referee, and have stated the limitations in the text. For
example we say: “Experimental verification of PTMs
discovered by mass spectrometry will be needed using
additional complementary techniques. It is also of note
that many of the studies have been performed on human
tumour or cancer cell line material; it is therefore con-
ceivable that some of these PTMs may be specific to tu-
mours, depending on the relative expression of different
modifying enzymes in cancerous and normal cells.” The
PhosphoSitePlus database is a manually curated database
of good quality, however most site assignments are not
linked with corresponding spectra at present. Therefore,
in order to place some measure of reliability on the basis
of the quality of evidence we have provided an additionallayer of annotation in the revised version (also see reply
to Reviewer 2 point 4, for discussion of false positive
rates). So for example where a specific experiment has
confirmed a particular site in the published literature,
and/or a number of five or more citations are associated
with a specific site from the high-throughput mass spec-
trometry screens in PhosphoSitePlus, we have now indi-
cated this in the table in a revised Additional file 2. It is
interesting that the majority of high-throughput sites
have been repeatedly seen in proteomic screens and thus
almost certainly represent true modifications (specifically,
for Phosphorylation: 22 out of 36; Acetylation: 11/25;
Methylation: 5/9; Ubiquitination: 23/25 have five or more
citations assigned to them in PhosphoSitePlus). We have
also prepared an additional figure to depict where these
more reliable PTM sites are located on the surface by
means of a comparison with Figure 1. As is readily appar-
ent in this new figure (Additional file 4), when only the
more reliable PTMs are considered, there remains an al-
most two-fold enhancement of post-translationally modi-
fied residues on the variable face (conserved face: 16
modified residues; variable face: 31 modified residues).
Third, there are serious issues to which extent PTMs
can occur in globular sections. The problem is that
protein-modifying enzymes have active site clefts/cavities
and the polypeptide stretch of the substrate protein has
to get somehow into it (Eisenhaber et al., Current Protein
and Peptide Science, 2007, 8, 197). The problem disap-
pears if there are auto-catalysis, non-enzymatic reac-
tions, modifications prior to substrate protein folding,
unstructured segments/long, conformationally variable
loops or unstable structural parts that readily unfold. It
would be necessary to substantiate what mechanism is
going on with eEF1A1/2 since this is part of the proof
that the PTM seen is biologically significant.
Authors’ Response: Again, the referee is right to make
this point. There are however, several PTMs that have
been confirmed by site-specific experiments, which
are indeed surface-exposed on more structured regions
(e.g. S21, K36, K165 on alpha-helices; E374 on beta-
strand etc.). The eEF1A1/eEF1A2 models [5] were based
upon the co-crystal structure of (~81% identical) yeast
eEF1A when bound to eEF1Balpha [28], so it is hard to
speculate on what conformational changes occur when
eEF1A transitions from free to bound forms. It is indeed
possible that protein-modifying enzymes access their
substrates in less globular forms of eEF1A. Some evi-
dence for less globular structure is provided in Budke-
vich et al. [17] who suggested that the eEF1A1 isoform
possesses an extended conformation in solution that
changes to an essentially more compact conformation
upon interaction with tRNAs. In support of such struc-
tural rearrangement, Negrutskii et al. [14] discussed tyro-
sine phosphorylation in the elongation factors from
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dues. While we can’t experimentally substantiate context-
dependent structural rearrangements in the current paper,
it is notable that (as yet) there is no evidence that
the eEF1A isoforms are bound to eEF1B (and therefore in
this structured conformation) when performing their
non-canonical roles in other functional pathways. Other
protein-interaction dependent PTM may also influence
accessibility of specific residues to their modifying en-
zymes. In sum, at least with respect to this “structured”
conformation of the eEF1As bound to eEF1Balpha, it does
seem highly unlikely that the observed clustering of PTMs
around sites of sequence variability on one face of the pro-
tein has occurred by chance. In response, we have updated
the main text so that it covers the substance of the above
observations.
Quality of written English: Acceptable.
Reviewer 2: Dr. Ramanathan Sowdhamini (Tata Institute
of Fundamental Research, India)
This manuscript by Soares and Abbott report the com-
parison of post-translational modification (PTM) data of
eEF1A isoforms. The two isoforms under analysis,
eEF1A1 and eEF1A2, exhibit differences in tissue local-
isation and affinity for GTP, despite sharing 91% identity
in amino acid sequence. These functional differences
have been addressed by the authors in the context of the
observed differences in patterns of PTM of the two pro-
teins. I would recommend publication of this manuscript
in Biology Direct, after the following points have been
addressed:
1. Page 4 onwards: terms like ‘front’ or ‘back’ of the pro-
tein sound too colloquial.
Authors’ Response: We have revised all text and figure
calls in the manuscript to refer to the previous ‘front’
side of the protein as the ‘conserved face’ and the ‘back’
side as the ‘variable face’ to highlight the eEF1A isoform
specific location of the sequence-variation in context of
this study.
2. Even in cases where PTM sites are conserved be-
tween eEF1A1 and eEF1A2, the molecular players re-
sponsible for PTM could be dramatically different. The
authors need to consider this point.
Authors’ Response: We thank the reviewer for mention-
ing this point. Indeed, it is very likely that the protein-
modifying enzymes involved could differ between isoforms,
even for sites that are identical in sequence. This may be in-
fluenced by minor differences in the neighbouring struc-
tural landscape of surface charge and hydrophobicity
proximal to the modified amino acid residue. We have in-
troduced this point in the penultimate paragraph of the
Findings discussion.
3. It will be interesting to compare such PTM motifs of
homologues - both closely related and distantly related -to provide a dimension of the role of PTM in the context
of evolutionary dynamics.
Authors’ Response: The referee is right. The issue with
extending the evolutionary analysis is one of available
data. Given the high similarity of the two isoforms
within a species, it is important to have some form of
additional evidence in order to assign sequences as un-
equivocally orthologous to either eEF1A1 or eEF1A2.
The best evidence comes from expression analysis; if
within a species there are two apparent eEF1A se-
quences and one is ubiquitously expressed but the other
expressed only in brain and muscle, it is possible to have
more confidence in their identity as eEF1A1 and eEF1A2
orthologues, respectively. Unfortunately such evidence is
almost entirely lacking for many species. Our Additional
file 1 displayed a multiple sequence alignment of various
eEF1A1 (10 species) and eEF1A2 (9 species) orthologues
from vertebrates. The modified residue is strictly con-
served in almost every case. Taking into account the
reviewer’s suggestion we have now added into the align-
ment the more divergent sequences of zebra fish and
also of non-vertebrate, but well characterised, yeast
eEF1A. This comparison illustrates clear alterations in
post-translational modifications between yeast compared
with other eukaryotic vertebrates – 18 sites in total.
These are indicated in the revised Additional file 1. The
presence of the two isoforms in vertebrates creates the
potential for greater complexity than is seen in yeast:
Saccharomyces cerevisiae has two genes encoding eEF1A
[29] and Schizosaccharomyces pombe has three [30], but
the encoded proteins are identical within a given species.
We thank the reviewer for this suggestion which clearly
points to gain of PTMs among vertebrates across evolu-
tion. We have summarised this point in the main text
along with the revised Additional file 1 and associated
legend.
4. Page 6 - It will be important to identify PTMs re-
corded for other proteins to note if there maybe false
positives.
Authors’ Response: Unless comprehensive comple-
mentary experimental validation of high-throughput
mass spectrometry studies are undertaken for the two
eEF1A isoforms and other proteins it will be difficult to
estimate false positive rates. Comparing examples of
other proteins as a means of assessing the likelihood of
false positives, depends on how that particular protein
has been researched. For example, for the comparatively
better-studied tumour suppressor protein, p53, a wide-
range of PTMs have been confirmed by site-specific
methods, which when compared to the mass spectrom-
etry (MS) screens in PhosphoSitePlus (http://www.phos-
phosite.org/proteinAction.do?id=465&showAllSites=true;
accessed 28th October, 2013) show that 95 modified po-
sitions exist in total across species, of which 80 were
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MS; of the 53 observed by MS, only 15 have yet to be
confirmed by a site-specific method. This indicates, at
least in this example, a very low false-positive rate; bear-
ing in mind that the rest of the MS sites are yet to be
verified independently. The p53 polypeptide is smaller
than eEF1As (p53, 393aa cf. 462/463aa for eEF1A1/
eEF1A2) but has a greater number of known and experi-
mentally verified PTMs. One of us recently published a
study on two highly similar paralogous proteins - NDE1
and NDEL1 - that possess similar structures [31] but are
differentially regulated post-translationally [32]. In that
case, nine out of ten sites verified by non-mass spec-
trometry experiments in the primary literature for NDE1
and NDEL1 were seen in the MS assignments in the
PhosphoSitePlus database. This suggests a high true
positive rate; additionally, >50% of sites assigned only
using the MS/high-throughput proteomics criteria had
five or more citations corresponding to each site in the
database, indicating a high potential for other sites to be
true positives too. There were also instances where ex-
perimentally confirmed sites had less than five associated
MS citations.
As mentioned in the main text and in our response to
Reviewer 1, because a lot of the data is based upon pub-
licly available high-throughput mass spectrometry data,
the assignments are probabilistic by nature and need to
be further confirmed experimentally by complementary
techniques such as site-directed mutagenesis, phospho-
specific antibodies and dominant-negative constructs.
Furthermore, future work should aim to ascertain the
specific kinases and other modifying molecular players.
Nonetheless, our structure-based mapping of PTMs in
context of sequence variation of the two eEF1A isoforms
and their putative binding sites form the baseline from
which future studies will continue to inform on the
regulation of these proteins.
Quality of written English: Acceptable.Additional files
Additional file 1: Alignment of eEF1A1 and eEF1A2 vertebrate
orthologues and yeast eEF1A with known PTMs mapped. Multiple
sequence alignment of vertebrate eEF1A1 (red box) and eEF1A2 (blue
box) is shown with strictly conserved residue positions depicted with a
black background and conservatively substituted or variable positions
with a white background [5]. The more divergent yeast eEF1A sequence
is also shown aligned below with sequence conservation depicted
relative to the vertebrate multiple sequence alignment; only those positions
that vary between yeast and the other sequences are shown with a white
background on the yeast sequence. Those PTM sites that are not conserved
in yeast are indicated with a solid-filled light blue rectangle. The known PTM
sites specific to one of eEF1A1 or eEF1A2 are shown within a yellow box
(T176A; C234T; K273R; S358A). The location of each PTM is denoted by a
symbol above the alignment block: phosphorylation: P; acetylation: A;
ubiquitination: U; methylation: M; ethanolamination: E; mono-O-glucosylation:
G; S-nitrosylation: N; S-glutathionylation: T; carbonylated peptide: C; wheremore than one modification occurs at a position this is shown separated by a
‘slash’ in a smaller font.
Additional file 2: Table of post-translational modifications (PTMs) in
eEF1A1 and eEF1A2. All experimentally derived, curated PTMs in the
eukaryotic translation elongation factors 1A1 and 1A2 from human,
mouse, rat, and rabbit are provided with corresponding references. The
list derives from curated information in the PhosphoSitePlus (www.
phosphosite.org; accessed August 2013) and UniProt databases [10,33],
literature involving specific PTM studies in eEF1As, and from both
low-throughput experimental methods and high-throughput tandem
mass spectrometry. Where data were obtained from mass spectrometric
studies from MS assignments from the Cell Signaling Technology
research group, the curated results from the PhosphoSitePlus team are
listed and referenced. High probability sites represented by five or more
references in the PhosphoSitePlus database or those confirmed by
experimentation are highlighted in blue (phosphorylation: 22/36; acetylation:
11/25; methylation: 5/9; ubiquitination: 23/25 have five or more citations
assigned to them in PhosphoSitePlus); these are mapped on the surface
of the 3-D model of eEF1A1 in Additional file 4. Amino acid substitutions
that are specific to eEF1A1 or eEF1A2 and that impact on PTMs are
highlighted in bold and a short description of the substitution is provided
where required.
Additional file 3: Post-translational modifications (PTMs) in
structural proximity to sequence variants between eEF1A1 and
eEF1A2. A total of 42 out of 67 (62.7%) PTM sites are located
structurally-proximal to a variant amino acid residue between eEF1A1
and eEF1A2; assessed using a 5-Å sphere radius probe measurement
around each variant amino acid on the 3-D model of human eEF1A1 [5]
under PyMol (www.pymol.org; The PyMOL Molecular Graphics System,
Version 0.99 Schrödinger, LLC). Those variants that are altered between
human eEF1A1 and eEF1A2 and are also sites of post-translational
modification are highlighted in bold. Note; there are an additional seven
PTM sites located in the unstructured C-terminus of the proteins that
harbour four additional sites of sequence variation between eEF1A1 and
eEF1A2, not shown. Out of the 42 PTMs located proximal to the variant
amino acid residues, a total of 33 are surface exposed at or proximal to
the two surface clusters of sequence variation (a total of 20 for cluster 1,
and 13 for cluster 2). Twelve of these cluster-proximal PTM sites are
modified more than once. Symbols added at the end of each PTM in the
table indicate: –p: phosphorylation; -a: acetylation; -m: methylation; -u:
ubiquitination; -e: glycerylphosphorylethanolamination; -n: S-nitrosylation; -t:
S-glutathionylation.
Additional file 4: Post-translational modifications (PTMs) by
strength of evidence mapped on surface of eEF1A1. (A) All
experimentally derived, curated PTMs in the eukaryotic translation
elongation factors 1A1 and 1A2 from human, mouse, rat, and rabbit are
shown mapped on the 3-D model of eEF1A1 as in Figure 1 in the main
text; refer to legend therein. (B) Only those sites represented by five or
more citations in the PhosphoSitePlus database or those confirmed by
site-specific experiment in the literature are shown on the 3-D model of
human eEF1A1. PTM residues that do not meet this criterion are labelled
in the upper frame (A) for comparison. The vast majority of surface exposed
residues that harbour PTMs are retained.Abbreviations
aa-tRNA: Aminoacylated-tRNA; eEF1A1: Eukaryotic translation elongation
factor 1 alpha 1; eEF1A2: Eukaryotic translation elongation factor 1 alpha 2;
PTM: Post-translational modification.Competing interests
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